Kindred Biosciences to Present at Cantor Global Healthcare Conference and Ladenburg Thalmann 2018 Healthcare Conference

SAN FRANCISCO, September 17, 2018 /PRNewswire/ — Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will present at the Cantor Global Healthcare Conference on October 1 and the Ladenburg Thalmann 2018 Healthcare Conference on October 2, 2018 in New York City.

Denise Bevers, Co-Founder and Chief Operating Officer, will present and be available for one-on-one meetings. During this time, investors will have the opportunity to discuss recent developments, including the launch of KindredBio’s first product, key therapeutic programs in development, and upcoming milestones.

Presentation Details:
Cantor Global Healthcare Conference
Date: Monday, October 1, 2018
Time: 1:45-2:15 PM ET
Location: InterContinental New York Barclay Hotel, Track 5 – Grand Ballroom 2
Webcast URL: Click here
Ladenburg Thalmann 2018 Healthcare Conference
Date: Tuesday, October 2, 2018
Time: 3:00-3:25 PM ET
Location: Sofitel New York, Track 4 – St. Germain III
Webcast URL: Click here
An archived version of the above webcasts will be available for 30 days on the Company’s website.

Important Safety Information
Mirataz® (mirtazapine transdermal ointment) is for topical use in cats only under veterinary supervision. Do not use in cats with a known hypersensitivity to mirtazapine or any of the excipients or in cats treated with monoamine oxidase inhibitors (MAOIs). Not for human use. Keep out of reach of children. Wear gloves to apply and wash hands after. Avoid contact with treated cat for 2 hours following application.  The most common adverse reactions include application site reactions, behavioral abnormalities (vocalization and hyperactivity) and vomiting. Please see the full Prescribing Information.

About Kindred Biosciences
Kindred Biosciences is a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company’s strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes. KindredBio’s first approved drug is Mirataz® (mirtazapine transdermal ointment) for the management of weight loss in cats.

For more information or to download the corporate presentation, visit Stay connected with KindredBio on Facebook at

Katja Buhrer
(917) 969-3438